NasoPass™ is our innovative intranasal delivery platform engineered to improve the administration of biological therapeutics, including vaccines, antibodies, proteins and peptides, directly to the nasal mucosa. By providing a more efficient route, NasoPass™ maximizes drug availability at the site of action.

For vaccination, NasoPass™ rapidly achieves high local concentrations in the nasopharynx, inducing secretory IgA and neutralizing antibodies to prevent initial infection and establish the respiratory tract’s first line of defense. It also enhances vaccine penetration across the nasal mucosa, ultimately triggering systemic IgG memory responses for broad, long-lasting protection.

For respiratory disease treatment, conventional antibody therapies require injections to achieve therapeutic levels because of their large molecular size. With NasoPass™ the same biologics are delivered directly to the disease site, substantially reducing the required dose while matching or exceeding the efficacy of injectable formulations and minimizing unnecessary systemic exposure and side effects.

NasoPass™ is ideally suited to the treatment of chronic rhinosinusitis, allergic rhinitis and upper respiratory tract infections. Its non-invasive, needle-free design is easy to use and ensures patient comfort, while delivering and sustaining therapeutic concentrations directly at the target site.